|
|
|
|
A randomized,double-blinded,placebo-controlled,clinical trial of low-dose, weekly,oral methotrexate was performed in 60 patients with clinically definite chronic progressive multiple sclerosis(MS)attending a referral- based outpatient MS clinic.Study patients were 21 to 60 years old with a disease duration of longer than 1 year.We conclude that low-dose,weekly, oral methotrexate offers a new,relatively nontoxic treatment option for patients with chronic progressive MS. |
|